$BDPT
BIOADAPTIVES, INC.

2022 Q3 Form 10-Q Financial Statement

#000164033422001749 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $3.337K $4.322K $5.533K
YoY Change -37.53% -28.74% 22.41%
Cost Of Revenue $1.337K $2.169K $3.590K
YoY Change -39.96% -20.05% 77.55%
Gross Profit $2.000K $2.153K $1.943K
YoY Change -35.79% -35.77% -22.16%
Gross Profit Margin 59.93% 49.81% 35.12%
Selling, General & Admin $74.57K $121.6K $143.0K
YoY Change -43.25% 146.56% -26.47%
% of Gross Profit 3728.5% 5649.33% 7361.3%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $4.470K $23.82K $33.17K
YoY Change -89.97% -7.03% 51.6%
% of Gross Profit 223.5% 1106.36% 1707.15%
Operating Expenses $79.05K $145.5K $176.2K
YoY Change -55.08% 94.05% -18.57%
Operating Profit -$77.05K -$143.3K -$174.3K
YoY Change -55.43% 100.13% -18.53%
Interest Expense $94.11K $75.37K $30.10K
YoY Change 45.8% 376.01% -50.99%
% of Operating Profit
Other Income/Expense, Net -$199.3K -$80.54K -$192.9K
YoY Change -244.05% -66.11% -30.62%
Pretax Income -$276.3K -$223.8K -$367.1K
YoY Change 700.59% -27.62% -25.37%
Income Tax
% Of Pretax Income
Net Earnings -$276.3K -$223.8K -$367.1K
YoY Change 700.57% -27.62% -25.37%
Net Earnings / Revenue -8280.64% -5179.01% -6635.3%
Basic Earnings Per Share
Diluted Earnings Per Share -$3.093K -$3.314K -$6.836K
COMMON SHARES
Basic Shares Outstanding 103.8M shares 67.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.94K $49.58K $55.96K
YoY Change -73.1% -29.44% 103.49%
Cash & Equivalents $17.91K $49.52K $55.79K
Short-Term Investments $30.00 $60.00 $170.00
Other Short-Term Assets $0.00 $1.000K $1.000K
YoY Change -100.0% -33.33%
Inventory $8.000K $10.65K $3.570K
Prepaid Expenses $0.00 $1.000K
Receivables
Other Receivables
Total Short-Term Assets $25.94K $61.23K $60.53K
YoY Change -66.43% -24.38% 46.6%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.674K $8.150K $26.54K
YoY Change -96.38% -85.18% -67.08%
TOTAL ASSETS
Total Short-Term Assets $25.94K $61.23K $60.53K
Total Long-Term Assets $3.674K $8.150K $26.54K
Total Assets $29.62K $69.38K $87.07K
YoY Change -83.43% -48.98% -28.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.340K $2.503K $324.9K
YoY Change -97.2% -97.01% 467.45%
Accrued Expenses $2.622K $3.146K $73.09K
YoY Change -95.26% -29.98%
Deferred Revenue
YoY Change
Short-Term Debt $434.1K $450.3K $427.4K
YoY Change -9.54% -13.91% -4.02%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.625M $1.564M $1.485M
YoY Change 16.86% 5.14% 27.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.625M $1.564M $1.485M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.625M $1.564M $1.485M
YoY Change 16.86% 5.14% 27.53%
SHAREHOLDERS EQUITY
Retained Earnings -$7.523M -$7.247M -$7.247M
YoY Change 16.79%
Common Stock $13.29K $7.746K
YoY Change 271.34% 134.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.596M -$1.495M -$1.398M
YoY Change
Total Liabilities & Shareholders Equity $29.62K $69.38K $87.07K
YoY Change -83.43% -48.98% -28.58%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$276.3K -$223.8K -$367.1K
YoY Change 700.57% -27.62% -25.37%
Depreciation, Depletion And Amortization $4.470K $23.82K $33.17K
YoY Change -89.97% -7.03% 51.6%
Cash From Operating Activities -$66.61K -$71.99K -$61.16K
YoY Change 100.75% 142.31% 1.32%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 35.00K 65.72K $34.01K
YoY Change 16.67% -12.37% -57.49%
NET CHANGE
Cash From Operating Activities -66.61K -71.99K -$61.16K
Cash From Investing Activities
Cash From Financing Activities 35.00K 65.72K $34.01K
Net Change In Cash -31.61K -6.270K -$27.15K
YoY Change 894.03% -113.84% -238.23%
FREE CASH FLOW
Cash From Operating Activities -$66.61K -$71.99K -$61.16K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001575142
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2021Q4 bdpt Common Stock Capital Shares Reserved For Future Issuance1
CommonStockCapitalSharesReservedForFutureIssuance1
10000 shares
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2022Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Entity File Number
EntityFileNumber
000-54949
dei Entity Registrant Name
EntityRegistrantName
BioAdaptives Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2592228
dei Entity Address Address Line1
EntityAddressAddressLine1
2620 Regatta Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89128
dei City Area Code
CityAreaCode
702
dei Local Phone Number
LocalPhoneNumber
659-8829
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
103813455 shares
CY2022Q2 us-gaap Cash
Cash
49517 usd
CY2021Q4 us-gaap Cash
Cash
82936 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77457483 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50819780 shares
CY2022Q2 bdpt Common Stock Capital Shares Reserved For Future Issuance1
CommonStockCapitalSharesReservedForFutureIssuance1
10000 shares
CY2022Q2 bdpt Weighted Average Number Of Common Shares Outstanding Basic And Diluted
WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
67545413 shares
CY2021Q2 bdpt Weighted Average Number Of Common Shares Outstanding Basic And Diluted
WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
33032425 shares
bdpt Weighted Average Number Of Common Shares Outstanding Basic And Diluted
WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
60677388 shares
bdpt Weighted Average Number Of Common Shares Outstanding Basic And Diluted
WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
30603899 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-1378785 usd
CY2021Q1 bdpt Stock Issued During Value Settlement For Debt
StockIssuedDuringValueSettlementForDebt
75000 usd
CY2021Q1 bdpt Series A Preferred Stock Issued For License Fee Amount
SeriesAPreferredStockIssuedForLicenseFeeAmount
102500 usd
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
486612 usd
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
163900 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-491903 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-1042676 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-309246 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-1351922 usd
us-gaap Net Income Loss
NetIncomeLoss
-590968 usd
us-gaap Net Income Loss
NetIncomeLoss
-801149 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
163900 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
167822 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
387723 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
56988 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
47500 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
79547 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
48048 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-51000 usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-127 usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
317 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5897 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3118 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
157431 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10103 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
1803 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-133147 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90074 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1623 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1623 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1623 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1623 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
25272 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
125000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
165000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
99728 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
155000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-33419 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
64926 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82936 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4587 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49517 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69513 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
4728 usd
us-gaap Interest Paid Net
InterestPaidNet
16424 usd
bdpt Derivative Liability Recognized As Debt Discount
DerivativeLiabilityRecognizedAsDebtDiscount
92000 usd
bdpt Derivative Liability Recognized As Debt Discount
DerivativeLiabilityRecognizedAsDebtDiscount
40000 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
173632 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
486612 usd
us-gaap Proceeds From Issuance Of Trust Preferred Securities
ProceedsFromIssuanceOfTrustPreferredSecurities
0 usd
us-gaap Proceeds From Issuance Of Trust Preferred Securities
ProceedsFromIssuanceOfTrustPreferredSecurities
102500 usd
bdpt Issuance Series A Preferred Stock For Settlement Of Debt Related Party
IssuanceSeriesAPreferredStockForSettlementOfDebtRelatedParty
0 usd
bdpt Issuance Series A Preferred Stock For Settlement Of Debt Related Party
IssuanceSeriesAPreferredStockForSettlementOfDebtRelatedParty
60 usd
bdpt Debts Forgiveness Related Party
DebtsForgivenessRelatedParty
10000 usd
bdpt Debts Forgiveness Related Party
DebtsForgivenessRelatedParty
0 usd
bdpt Warrant Issued For Patents Acquisition
WarrantIssuedForPatentsAcquisition
5429 usd
bdpt Warrant Issued For Patents Acquisition
WarrantIssuedForPatentsAcquisition
0 usd
bdpt Cancellation Of Common Stock
CancellationOfCommonStock
0 usd
bdpt Cancellation Of Common Stock
CancellationOfCommonStock
35 usd
bdpt Owned Subsidiaries Percentage
OwnedSubsidiariesPercentage
1 pure
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
55917 usd
CY2022Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
63 usd
CY2022Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
722664 usd
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
190 usd
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
557042 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
25272 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
10000 usd
CY2022Q2 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
4728 usd
CY2021Q2 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
0 usd
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7247077 usd
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
63 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
190 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
47500 usd
bdpt License Cost
LicenseCost
3792 usd
bdpt License Cost
LicenseCost
59709 usd
bdpt Amortization Of Intangible Assets1
AmortizationOfIntangibleAssets1
1071 usd
CY2022Q2 bdpt Asset Value Of The Patent
AssetValueOfThePatent
4358 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
25556 usd
CY2022Q2 bdpt Convertible Notes Accrued Interest
ConvertibleNotesAccruedInterest
84873 usd
bdpt Amortization Of Debt Discount
AmortizationOfDebtDiscount
79547 usd
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75650 usd
CY2022Q2 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
94200 usd
bdpt Debt Discount
DebtDiscount
92000 usd
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
28960 usd
bdpt Beginning Balance
BeginningBalance
557042 usd
bdpt Addition Of New Derivatives Recognized As Debt Discounts
AdditionOfNewDerivativesRecognizedAsDebtDiscounts
92000 usd
bdpt Addition Of New Derivatives Recognized As Loss On Derivatives
AdditionOfNewDerivativesRecognizedAsLossOnDerivatives
28960 usd
bdpt Settled On Issuance Of Common Stock
SettledOnIssuanceOfCommonStock
-94200 usd
bdpt Gain Loss On Change In Fair Value Of The Derivative Liabilities
GainLossOnChangeInFairValueOfTheDerivativeLiabilities
138862 usd
bdpt Ending Balance
EndingBalance
722664 usd
bdpt Loss On Derivative Instruments Related Convertible Notes
LossOnDerivativeInstrumentsRelatedConvertibleNotes
28960 usd
bdpt Loss On Derivative Instruments Related Convertible Notes
LossOnDerivativeInstrumentsRelatedConvertibleNotes
101805 usd
bdpt Gain Loss On Change In Fair Value Of The Derivative Liabilities
GainLossOnChangeInFairValueOfTheDerivativeLiabilities
138862 usd
bdpt Gain Loss On Change In Fair Value Of The Derivative Liabilities
GainLossOnChangeInFairValueOfTheDerivativeLiabilities
285918 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
167822 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
387723 usd
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
26637703 shares
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
173632 usd
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77457483 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50809780 shares
CY2022Q1 bdpt Common Stock Shares Granted
CommonStockSharesGranted
1000000 shares
CY2022Q1 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
0.006
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5429 usd
us-gaap Interest Paid
InterestPaid
363 usd
us-gaap Interest Paid
InterestPaid
1055 usd
CY2022Q2 bdpt Notes Payable Related Party
NotesPayableRelatedParty
8443 usd
CY2021Q4 bdpt Notes Payable Related Party
NotesPayableRelatedParty
33715 usd
CY2022Q2 bdpt Notes Payable Accrude Interest
NotesPayableAccrudeInterest
876 usd
CY2021Q4 bdpt Notes Payable Accrude Interest
NotesPayableAccrudeInterest
5241 usd
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.04 pure
bdpt Accrued Salary
AccruedSalary
133334 usd
CY2022Q2 bdpt Accrued Salary Payable
AccruedSalaryPayable
10000 usd

Files In Submission

Name View Source Status
0001640334-22-001749-index-headers.html Edgar Link pending
0001640334-22-001749-index.html Edgar Link pending
0001640334-22-001749.txt Edgar Link pending
0001640334-22-001749-xbrl.zip Edgar Link pending
bdpt-20220630.xsd Edgar Link pending
bdpt_10q.htm Edgar Link pending
bdpt_10qimg2.jpg Edgar Link pending
bdpt_ex311.htm Edgar Link pending
bdpt_ex312.htm Edgar Link pending
bdpt_ex321.htm Edgar Link pending
bdpt_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
bdpt-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bdpt-20220630_cal.xml Edgar Link unprocessable
bdpt-20220630_pre.xml Edgar Link unprocessable
bdpt-20220630_lab.xml Edgar Link unprocessable
bdpt_10q_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending